LOW DOSE ORAL FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH UNTREATED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Forconi, F. [1 ]
Fabbri, A. [1 ]
Lenoci, M. [1 ]
Sozzi, E. [1 ]
Bocchia, M. [1 ]
Gozzetti, A. [1 ]
Tassi, M. [1 ]
Raspadori, D. [1 ]
Lauria, F. [1 ]
机构：
[1] Univ Siena, I-53100 Siena, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0093
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [41] THE EFFICACY OF FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINATION IN UNTREATED VS PRETREATED PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
    Milosevic, V.
    Bogunovic, M.
    Jankovic, S.
    Antic, D.
    Tomin, D.
    Todorovic, M.
    Kurtovic, N. Kraguljac
    Jovanovic, M. Perunicic
    Bogdanovic, A.
    Mihaljevic, B.
    Gotic, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 527 - 527
  • [42] COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE
    Roussel, M.
    Troussard, X.
    Delmer, A.
    Poinso, M.
    Miadi-Fargier, H.
    VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
  • [43] Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Wierda, W. G.
    Kipps, T. J.
    Duerig, J.
    Griskevicius, L.
    Stilgenbauer, S.
    Mayer, J.
    Gorczyca, M.
    Andersen, M.
    Nielsen, T.
    Russell, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3)
    Robak, Tadeusz
    Blonski, Jerzy Z.
    Jamroziak, Krzysztof
    Gora-Tybor, Joanna
    Stella-Holowiecka, Beata
    Konopka, Lech
    Ceglarek, Bernadeta
    Warzocha, Krzysztof
    Seferynska, Ilona
    Kloczko, Janusz
    Piszcz, Jaroslaw
    Calbecka, Malgorzata
    Kostyra, Aleksandra
    Dwilewicz-Trojaczek, Jadwiga
    Wiater, Elzbieta
    Dmoszynska, Anna
    Kowal, Malgorzata
    Zawilska, Krystyna
    Grzywacz, Alina
    Hellmann, Andrzej
    Mital, Andrzej
    Zdunczyk, Andrzej
    Dybowicz, Jacck
    Kuliczkowski, Kazimierz
    Potoczek, Stanislaw
    Skotnicki, Aleksander
    Nowakowska-Domagala, Maria
    Lewandowski, Krzysztf
    Sulek, Kazimierz
    BLOOD, 2008, 112 (11) : 732 - 732
  • [45] A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
    Izutsu, Koji
    Kinoshita, Tomohiro
    Takizawa, Jun
    Fukuhara, Suguru
    Yamamoto, Go
    Ohashi, Yasuo
    Suzumiya, Junji
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 408 - 415
  • [46] Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706
    M A Hussein
    H Gundacker
    D R Head
    L Elias
    K A Foon
    D H Boldt
    S M Dobin
    S R Dakhil
    G T Budd
    F R Appelbaum
    Leukemia, 2005, 19 : 1880 - 1886
  • [47] Health-related quality of life in elderly patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy
    Tschechne, B.
    Detken, S.
    Eschenburg, H.
    Gaede, B.
    Goehler, T.
    Hansen, R.
    Hutzschenreuter, U.
    Kluck, C.
    Marquard, F.
    Mueller, L.
    Nawka, S.
    Schardt, C.
    Scheuer, B.
    Schulze, M.
    Soeling, U.
    Tessen, H. W.
    Uhlig, J.
    Weniger, J.
    Wolf, H.
    Wysk, J.
    ONKOLOGIE, 2008, 31 : 122 - 122
  • [48] Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia
    Shvidel, L
    Shtalrid, M
    Bairey, O
    Rahimi-Levene, N
    Lugassy, G
    Shpilberg, O
    Polliack, A
    Berrebi, A
    LEUKEMIA & LYMPHOMA, 2003, 44 (11) : 1947 - 1950
  • [49] A phase II study investigating safety and efficacy of dose reduced fludarabine, cyclophosphamide and obinutuzumab versus chlorambucil and obinutuzumab in untreated, comorbid, elderly patients with chronic lymphocytic leukemia (CLL)
    Mulligan, Stephen
    Tam, Constantine
    Badoux, Xavier
    Kuss, Bryone
    LEUKEMIA & LYMPHOMA, 2015, 56 : 25 - 26
  • [50] Early clinical and pharmacokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL).
    Tarhini, Ahmad A.
    Land, S.
    Meisner, D.
    Pietragallo, L.
    Sulecki, M.
    Lim, F.
    Kiefer, Gauri J.
    Pinkerton, R.
    Obsom, J.
    Sukaly, S.
    Schaefer, P. M.
    Foon, Kenneth A.
    BLOOD, 2006, 108 (11) : 805A - 805A
12345